The United States Food and Drug Administration (USFDA) has issued seven inspectional observations at Alkem Laboratories Limited's manufacturing facility in Amaliya, Daman, following a comprehensive regulatory inspection. According to reports from CNBC TV18, the inspection was conducted over a 12-day period from April 20 to May 1, resulting in the formal issuance of Form 483 by the FDA. An FDA Form 483, officially known as the 'Notice of Inspectional Observations,' is issued when investigators identify conditions that may represent violations of the Food, Drug and Cosmetic (FD&C) Act regulations. The inspection was conducted over an 11-day period from April 20, 2026 to May 1, 2026, as confirmed by ScanXNews, with the facility located in Amaliya, Daman.
Following the completion of the inspection, Alkem Laboratories has acknowledged receipt of the observations and stated that it will address all seven points raised by the regulator within the stipulated timeframe. As reported by CNBC TV18, the company formally disclosed this update to Indian stock exchanges, BSE Limited and National Stock Exchange of India Limited, as part of its mandatory regulatory compliance obligations on May 2, 2026. The disclosure was made through proper corporate governance channels, with the communication signed by Manish Narang, President-Legal, Company Secretary and Compliance Officer, ensuring compliance with regulatory requirements. However, the pharmaceutical major did not provide specific details regarding the nature of the observations raised by the FDA.
This development follows the company's announcement in March that its manufacturing facility in Daman, India, had received a Certificate of GMP Compliance from the Malta Medicines Authority. According to CNBC TV18, the certificate was issued after an inspection conducted on December 9, 2025, and remains valid for three years. The approval confirms compliance with European Union Good Manufacturing Practices (EU GMP) standards, with the certificate being granted after an earlier inspection by the Malta Medicines Authority disclosed by Alkem Laboratories on December 10 last year.
The regulatory developments come amid significant leadership changes at Alkem Laboratories, with CEO Dr. Vikas Gupta's resignation formally disclosed through regulatory filing on April 24, 2026. As per ScanXNews, Dr. Gupta will continue until June 30, 2026 to ensure seamless transition of strategic initiatives and leadership responsibilities, while pursuing new professional opportunities. In his formal resignation letter, Dr. Gupta expressed gratitude for his tenure and highlighted the company's achievements during his leadership, emphasizing the foundation built positions the company well for its next chapter of growth. The leadership transition occurs during a period of regulatory compliance requirements, with the company maintaining its commitment to addressing both the FDA observations and the upcoming leadership transition.
